Nov 6, 2017 - Background: Studies have shown that metformin is associated with reduced cancer risk in diabetic patients. However, evidence on its effect on ...
Table 8: Metformin Therapy is not associated with Risk of Endometrial Cancer in Diabetic patients: A MetaAnalysis of cohort and casecontrol studies on 534,755 subjects Monday, November 06, 2017 10:30 AM 12:00 PM
Authors Xiaotao Zhang
Eeshwar Chandrasekar
University of Texas, MD Anderson Cancer Center
School of Medicine, Emory University, Atlanta, GA
Jingkai Wei
Tiansheng Wang
University of North Carolina at Chapel Hill, Chapel Hill, NC
University of North Carolina at Chapel Hill, Chapel Hill, NC
Haidong Lu University of North Carolina at Chapel Hill, Chapel Hill, NC
Background: Studies have shown that metformin is associated with reduced cancer risk in diabetic patients. However, evidence on its effect on endometrial cancer is limited and inconsistent. To assess the effect of metformin on cancer incidence and mortality in diabetic patients, we performed a metaanalysis of available studies on this issue. Methods: We systematically searched PubMed, Embase and Web of Science for observational studies that examined the association between metformin and risk of endometrial cancer among diabetic patients. Use of metformin was compared with nonuse of metformin among diabetic patients for risk of endometrial cancer. A randomeffect model was fitted to estimate the summary relative risk (RR) and 95% confidence interval (CI). Between studies heterogeneity was measured with the I square statistic. Results: Five studies met the inclusion criteria and a total of 534,755 diabetic patients were included in the metaanalysis. Heterogeneity existed among different studies (I2=96.4%, p
